PapersPMID:28658720
Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.
What moved
1 findingHow to read these marks →- Decreases necrotising enterocolitis incidence
very limited
“Trial results show that lactoferrin supplementation to enteral feeds decreased late-onset sepsis (typical risk ratio (RR) 0.59, 95% confidence interval (CI) 0.40 to 0.87; typical risk difference (RD) -0.06, 95% CI -0.10 to -0.02; number needed to treat for an additional beneficial outcome (NNTB) 17, 95% CI 10 to 50; six trials, 886 participants; low-quality evidence) and NEC stage II or III (typical RR 0.40, 95% CI 0.18 to 0.86; typical RD -0.04, 95% CI -0.06 to -0.01; NNTB 25, 95% CI 17 to 100; four studies, 750 participants; low-quality evidence).”
- Study
- meta-analysis
- Participants
- 750
- Effect
- 0.4 risk ratio, 95% CI 0.18 to 0.86
- Population
- preterm neonates, lactoferrin added to enteral feeds (4 trials pooled); NEC counted at stage II or III
Study record
- Design
- meta-analysis
- Species
- human / none
- Population
- Preterm neonates in RCTs of oral/enteral lactoferrin supplementation (lactoferrin type, human or bovine, not specified in the abstract), with or without probiotics; six RCTs pooled. Abstract only.
- Participants
- not reported
- Comparator
- not stated in the paper
- Duration
- not reported
- Endpoints measured
- 10